

# David A Rizzieri

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2340161/publications.pdf>

Version: 2024-02-01

175  
papers

4,441  
citations

159585

30  
h-index

114465

63  
g-index

176  
all docs

176  
docs citations

176  
times ranked

6358  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuclear factor- $\kappa$ B is constitutively activated in primitive human acute myelogenous leukemia cells. <i>Blood</i> , 2001, 98, 2301-2307.	1.4	695
2	The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia. <i>Blood</i> , 2018, 131, 2661-2669.	1.4	313
3	Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm. <i>New England Journal of Medicine</i> , 2019, 380, 1628-1637.	27.0	274
4	Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. <i>Lancet Oncology</i> , The, 2015, 16, 1099-1110.	10.7	249
5	A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Clinical Cancer Research</i> , 2008, 14, 2756-2762.	7.0	233
6	Partially Matched, Nonmyeloablative Allogeneic Transplantation: Clinical Outcomes and Immune Reconstitution. <i>Journal of Clinical Oncology</i> , 2007, 25, 690-697.	1.6	188
7	Guadecitabine (SGI-110) in treatment-naïve patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1317-1326.	10.7	148
8	Lis1 regulates asymmetric division in hematopoietic stem cells and in leukemia. <i>Nature Genetics</i> , 2014, 46, 245-252.	21.4	97
9	The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. <i>Blood</i> , 2020, 136, 130-136.	1.4	97
10	Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma. <i>Cancer</i> , 2004, 100, 1438-1448.	4.1	96
11	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. <i>Blood Advances</i> , 2019, 3, 1826-1836.	5.2	89
12	CD98-Mediated Adhesive Signaling Enables the Establishment and Propagation of Acute Myelogenous Leukemia. <i>Cancer Cell</i> , 2016, 30, 792-805.	16.8	86
13	A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma. <i>British Journal of Haematology</i> , 2017, 178, 434-441.	2.5	86
14	Natural Killer Cell-Enriched Donor Lymphocyte Infusions from A 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1107-1114.	2.0	79
15	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10A002. <i>British Journal of Haematology</i> , 2014, 165, 102-111.	2.5	78
16	Systematic Dissection of the Metabolic-Apoptotic Interface in AML Reveals Heme Biosynthesis to Be a Regulator of Drug Sensitivity. <i>Cell Metabolism</i> , 2019, 29, 1217-1231.e7.	16.2	75
17	Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 726-733.	2.0	71
18	Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and <i>IDH1/2</i> Mutations. <i>Clinical Cancer Research</i> , 2022, 28, 2753-2761.	7.0	70

#	ARTICLE	IF	CITATIONS
19	Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. <i>Clinical Infectious Diseases</i> , 2016, 63, 999-1006.	5.8	63
20	Tetraspanin 3 Is Required for the Development and Propagation of Acute Myelogenous Leukemia. <i>Cell Stem Cell</i> , 2015, 17, 152-164.	11.1	58
21	An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 1800-1806.	1.3	57
22	Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. <i>Cancer</i> , 2018, 124, 325-334.	4.1	57
23	Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen. <i>Blood</i> , 2001, 98, 3486-3488.	1.4	53
24	Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma. <i>Blood</i> , 2004, 104, 642-648.	1.4	53
25	Alemtuzumab for the prevention and treatment of graft-versus-host disease. <i>International Journal of Hematology</i> , 2011, 93, 586-593.	1.6	53
26	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. <i>Blood</i> , 2001, 97, 2177-2179.	1.4	51
27	A phase 1 study of the pan- $\beta$ -bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia. <i>Cancer</i> , 2021, 127, 2943-2953.	4.1	42
28	A Phase 1 Study of the DOT1L Inhibitor, Pinometostat (EPZ-5676), in Adults with Relapsed or Refractory Leukemia: Safety, Clinical Activity, Exposure and Target Inhibition. <i>Blood</i> , 2015, 126, 2547-2547.	1.4	42
29	Outcomes of Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma Transformed from Follicular Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 951-959.	2.0	37
30	Phase I Evaluation of Prolonged-Infusion Gemcitabine With Mitoxantrone for Relapsed or Refractory Acute Leukemia. <i>Journal of Clinical Oncology</i> , 2002, 20, 674-679.	1.6	36
31	Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357.	5.2	35
32	Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>IDH 1/2</i> Mutations. <i>Blood</i> , 2020, 136, 5-7.	1.4	28
33	Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia. <i>Cancer</i> , 2009, 115, 2922-2929.	4.1	26
34	Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. <i>Leukemia Research</i> , 2020, 95, 106385.	0.8	26
35	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	1.4	26
36	Results from Ongoing Phase 2 Trial of SL-401 As Consolidation Therapy in Patients with Acute Myeloid Leukemia (AML) in Remission with High Relapse Risk Including Minimal Residual Disease (MRD). <i>Blood</i> , 2016, 128, 215-215.	1.4	25

#	ARTICLE	IF	CITATIONS
37	First Clinical Results Of a Randomized Phase 2 Study Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In Adult Patients With Acute Myeloid Leukemia (AML). <i>Blood</i> , 2013, 122, 497-497.	1.4	23
38	A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. <i>American Journal of Hematology</i> , 2015, 90, 796-799.	4.1	21
39	Insight into the molecular pathophysiology of myelodysplastic syndromes: targets for novel therapy. <i>European Journal of Haematology</i> , 2016, 97, 313-320.	2.2	21
40	Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery. <i>Journal of Hematology and Oncology</i> , 2016, 9, 71.	17.0	20
41	Activity and tolerability of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, as a single agent in patients with advanced hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2013, 31, 7029-7029.	1.6	19
42	Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm. <i>Journal of Clinical Oncology</i> , 2022, 40, 3032-3036.	1.6	19
43	Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma. <i>Cancer</i> , 2004, 100, 2408-2414.	4.1	18
44	Assessing the Feasibility of a Novel mHealth App in Hematopoietic Stem Cell Transplant Patients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 181.e1-181.e9.	1.2	18
45	Efficacy and Toxicity of Rituximab and Brief Duration, High Intensity Chemotherapy with Filgrastim Support for Burkitt or Burkitt " Like Leukemia/Lymphoma: Cancer and Leukemia Group B (Calgb) Study 10002. <i>Blood</i> , 2010, 116, 858-858.	1.4	17
46	Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemia. <i>Clinical Cancer Research</i> , 2003, 9, 663-8.	7.0	17
47	First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7502-7502.	1.6	16
48	Reduced-Intensity Allogeneic Transplantation Using Alemtuzumab from HLA-Matched Related, Unrelated, or Haploidentical Related Donors for Patients with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 257-263.	2.0	15
49	Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response. <i>Frontiers in Oncology</i> , 2018, 8, 669.	2.8	15
50	Phase I dose escalation study of naive T-cell depleted donor lymphocyte infusion following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 137-143.	2.4	15
51	Comparison of outcomes of HCT in blast phase of <i>t(9;22) BCR-ABL1</i> MPN with de novo AML and with AML following MDS. <i>Blood Advances</i> , 2020, 4, 4748-4757.	5.2	14
52	Overall survival (OS) with CPX-351 versus 7+3 in older adults with newly diagnosed, therapy-related acute myeloid leukemia (tAML): Subgroup analysis of a phase III study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7035-7035.	1.6	14
53	Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7030-7030.	1.6	14
54	Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses. <i>Blood Advances</i> , 2021, 5, 1719-1728.	5.2	13

#	ARTICLE	IF	CITATIONS
55	First-in-human study of ABBV-075 (mivebresib), a pan-inhibitor of bromodomain and extra terminal (BET) proteins, in patients (pts) with relapsed/refractory (RR) acute myeloid leukemia (AML): Preliminary data.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7019-7019.	1.6	12
56	A phase II study of elacytarabine in combination with idarubicin and of human equilibrative nucleoside transporter 1 expression in patients with acute myeloid leukemia and persistent blasts after the first induction course. <i>Leukemia and Lymphoma</i> , 2014, 55, 2114-2119.	1.3	11
57	Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis. <i>Leukemia and Lymphoma</i> , 2019, 60, 2384-2393.	1.3	11
58	A Phase 2 Study of Actinium-225 (225Ac)-Lintuzumab in Older Patients with Untreated Acute Myeloid Leukemia (AML) - Interim Analysis of 1.5 Åµci/Kg/Dose. <i>Blood</i> , 2018, 132, 1457-1457.	1.4	11
59	Results From the Dose Escalation Phase of a Randomized Phase 1â€² First-in-Human (FIH) Study of SGI-110, a Novel Low Volume Stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in Patients with Relapsed/Refractory MDS and AML. <i>Blood</i> , 2012, 120, 414-414.	1.4	11
60	Results from phase 2 registration trial of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): Lead-in completed, expansion stage ongoing.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7006-7006.	1.6	11
61	Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity. <i>Advances in Radiation Oncology</i> , 2016, 1, 272-280.	1.2	10
62	Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1930-1936.	2.0	10
63	SL-401, A Targeted Therapy Directed to the Interleukin-3 Receptor Present On Leukemia Blasts and Cancer Stem Cells, Is Active As a Single Agent in Patients with Advanced AML. <i>Blood</i> , 2012, 120, 3625-3625.	1.4	10
64	Results of Pivotal Phase 2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). <i>Blood</i> , 2018, 132, 765-765.	1.4	9
65	Impact of High Dose Cyclophosphamide on the Outcome of Autologous Stem Cell Transplant in Patients with Newly Diagnosed Multiple Myeloma,. <i>Blood</i> , 2011, 118, 4127-4127.	1.4	9
66	A phase I/II study of IMGN632, a novel CD123-targeting antibody-drug conjugate, in patients with relapsed/refractory acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm, and other CD123-positive hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS7563-TPS7563.	1.6	9
67	P2RY2-AKT activation is a therapeutically actionable consequence of XPO1 inhibition in acute myeloid leukemia. <i>Nature Cancer</i> , 2022, 3, 837-851.	13.2	9
68	Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity. <i>Leukemia and Lymphoma</i> , 2005, 46, 1455-1462.	1.3	8
69	MK-0457, a Novel Multikinase Inhibitor, Has Activity in Refractory AML, Including Transformed JAK2 Positive Myeloproliferative Disease (MPD), and in Philadelphia-Positive ALL.. <i>Blood</i> , 2006, 108, 1967-1967.	1.4	8
70	Microtransplantation in older patients with <scp>AML</scp>: A pilot study of safety, efficacy and immunologic effects. <i>American Journal of Hematology</i> , 2020, 95, 662-671.	4.1	7
71	Chlorhexidine Gluconate Bathing Reduces the Incidence of Bloodstream Infections in Adults Undergoing Inpatient Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 262.e1-262.e11.	1.2	7
72	Comparison of Efficacy and Safety Results in 103 Treatment-NaÃve Acute Myeloid Leukemia (TN-AML) Patients Not Candidates for Intensive Chemotherapy Using 5-Day and 10-Day Regimens of Guadecitabine (SGI-110), a Novel Hypomethylating Agent (HMA). <i>Blood</i> , 2015, 126, 458-458.	1.4	7

#	ARTICLE	IF	CITATIONS
73	A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.. Journal of Clinical Oncology, 2017, 35, TPS7070-TPS7070.	1.6	7
74	Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access) Tj ETQq0100 rgBT hOverlock 1	1.4	6
75	Phase II Study of Single-Agent and Combination Everolimus and Panobinostat in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Cancer Investigation, 2021, 39, 871-879.	1.3	6
76	Maintenance Therapy with Low-Dose Subcutaneous 5-Azacitidine in Older Patients with AML in 1st Remission.. Blood, 2009, 114, 1029-1029.	1.4	6
77	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. Blood, 2017, 130, 891-891.	1.4	6
78	Efficacy and safety of high-dose chemotherapy with autologous stem cell transplantation in senior versus younger adults with newly diagnosed multiple myeloma. Hematological Oncology, 2017, 35, 752-759.	1.7	5
79	Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN).. Journal of Clinical Oncology, 2021, 39, e19043-e19043.	1.6	5
80	Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>KMT2A</i>-rearranged AML. Blood Advances, 2022, 6, 828-847.	5.2	5
81	A Phase 2 Clinical Trial of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.. Blood, 2005, 106, 2980-2980.	1.4	5
82	Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.. Blood, 2009, 114, 2201-2201.	1.4	5
83	Nilotinib Responses and Tolerability Confirmed in North American Patients with Chronic Myeloid Leukemia (CML) From ENACT (Expanding Nilotinib Access in Clinical Trials).. Blood, 2009, 114, 3295-3295.	1.4	5
84	Partially HLA Matched, Non-Myeloablative Allogeneic Transplantation.. Blood, 2005, 106, 2896-2896.	1.4	5
85	Feasibility of Low-Dose Interleukin-2 Therapy Following T-Cell-Depleted Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation From HLA-Matched or -Mismatched Family Member Donors. Cancer Investigation, 2011, 29, 56-61.	1.3	4
86	Pre-transplant hepatic steatosis (fatty liver) is associated with chronic graft-vs-host disease but not mortality. PLoS ONE, 2020, 15, e0238824.	2.5	4
87	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer, 2021, 127, 4421-4431.	4.1	4
88	Female Sex Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy, 2021, 27, 784.e1-784.e7.	1.2	4
89	Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. Transplantation and Cellular Therapy, 2021, 27, 993.e1-993.e8.	1.2	4
90	A Phase I Study of Talvesta® (Talotrexin) in Relapsed or Refractory Leukemia or Myelodysplastic Syndrome.. Blood, 2006, 108, 1968-1968.	1.4	4

#	ARTICLE	IF	CITATIONS
91	Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study.. Blood, 2009, 114, 1047-1047.	1.4	4
92	Monosomal Karyotype Is Predictive of Poor Response to Therapy and Worse Overall Survival in Secondary Acute Myeloid Leukemia (sAML); Analysis of a Multi-Center Phase II Study of Amonafide and Cytarabine Induction Therapy.. Blood, 2009, 114, 2076-2076.	1.4	4
93	A Phase I/II Trial of the Potent Hsp90 Inhibitor STA-9090 Administered Once Weekly In Patients with Advanced Hematologic Malignancies. Blood, 2010, 116, 3294-3294.	1.4	4
94	A phase II study of single agent mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in patients with diffuse large cell B-cell (DLBCL) and follicular (FL) lymphomas.. Journal of Clinical Oncology, 2013, 31, 8535-8535.	1.6	4
95	First results of a phase 2 study using a 10-day subcutaneous (SC) regimen of the novel hypomethylating agent (HMA) SGI-110 for the treatment of relapsed/refractory acute myeloid leukemia (r/r AML).. Journal of Clinical Oncology, 2014, 32, 7030-7030.	1.6	4
96	ET190L1-ARTEMIS T cell therapy to induce complete remission of relapsed and refractory (r/r) B-cell lymphoma with no cytokine release syndrome in the first-in-human clinical study.. Journal of Clinical Oncology, 2018, 36, 3049-3049.	1.6	4
97	A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. PLoS ONE, 2021, 16, e0252995.	2.5	3
98	Phase III Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin's Lymphoma (EXTEND): Results From the Treatment and Follow-up Periods.. Blood, 2009, 114, 1677-1677.	1.4	3
99	Phase I Trial Results for SL-401, a Novel Cancer Stem Cell (CSC) Targeting Agent, Demonstrate Clinical Efficacy at Tolerable Doses In Patients with Heavily Pre-Treated AML, Poor Risk Elderly AML, and High Risk MDS. Blood, 2010, 116, 3298-3298.	1.4	3
100	ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.. Journal of Clinical Oncology, 2018, 36, TPS3102-TPS3102.	1.6	3
101	A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients with Chronic Myeloid Leukemia (CML) and Molecular Residual Disease after Tyrosine Kinase Inhibitor (TKI) Therapy. Blood, 2020, 136, 5-5.	1.4	3
102	Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant. Blood Cancer Journal, 2021, 11, 92.	6.2	2
103	Histone Deacetylase Inhibition Using LBH589 Is Effective in Lymphoma and Results in Down-Regulation of the NF-KB Pathway.. Blood, 2009, 114, 3730-3730.	1.4	2
104	Phase 3 Trial of Pixantrone Dimaleate Compared with Other Agents as Third-Line, Single-Agent Treatment of Relapsed Aggressive Non-Hodgkin Lymphoma (EXTEND): End of Study Results.. Blood, 2010, 116, 2833-2833.	1.4	2
105	High Complete Response Rates with Dose Dense/Dose Intense Chemotherapy Plus Radioimmunotherapy in High Risk Diffuse Large B Cell and Mantle Cell Lymphoma. Blood, 2011, 118, 2681-2681.	1.4	2
106	Phase II Trial of Sorafenib in Myelodysplastic Syndrome: A Single Institution Experience. Blood, 2011, 118, 5021-5021.	1.4	2
107	Final Clinical Results with Laboratory Correlates in the Phase I Trial of Lenalidomide Plus Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL). Blood, 2014, 124, 5658-5658.	1.4	2
108	A phase 1, open-label, dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and activity of ADCT-301 in patients with relapsed or refractory CD25-positive acute myeloid leukemia.. Journal of Clinical Oncology, 2016, 34, TPS7071-TPS7071.	1.6	2

#	ARTICLE	IF	CITATIONS
109	Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, , .	2.4	2
110	Doseâ€intense chemoimmunotherapy plus radioimmunotherapy in highâ€risk diffuse large Bâ€cell lymphoma and mantle cell lymphoma: a phase <scp>ll</scp> study. British Journal of Haematology, 2019, 184, 647-650.	2.5	1
111	Campath-1H May Have Activity in the Treatment of Multiple Myeloma.. Blood, 2004, 104, 4931-4931.	1.4	1
112	Feasibility Study of a Dose Dense Induction Regimen of High Dose Cytarabine (HiDAC) and Gemtuzumab Ozogamicin (Mylotargâ„¢) for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia.. Blood, 2005, 106, 4610-4610.	1.4	1
113	A Prospective Study of Bortezomib in Combination with Melphalan and Prednisone for Patients with Previously Untreated Multiple Myeloma.. Blood, 2005, 106, 5181-5181.	1.4	1
114	Adult Umbilical Cord Blood Transplantation Following Non-Myeloablative Conditioning; Impact of Increased Cell Dose and 200cGy TBI on Engraftment and Survival.. Blood, 2006, 108, 5399-5399.	1.4	1
115	Cytotoxicity of the Type 4 Phosphodiesterase Inhibitor CD160130 for Freshly Isolated Human CLL Cells In Vitro.. Blood, 2007, 110, 3129-3129.	1.4	1
116	Secondary Acute Myeloid Leukemia (sAML) Treated with Amonafide (AS1413) + Cytarabine: Durable Responses in Poor-Risk AML. Blood, 2008, 112, 2968-2968.	1.4	1
117	Safety Trial of NK Cell Enhanced Donor Lymphocyte Infusions from a 3-5/6 HLA Matched Family Member Following Nonmyeloablative Allogeneic Stem Cell Transplantation. Blood, 2008, 112, 342-342.	1.4	1
118	PI3K Inhibitors Inhibit Lymphoma Growth by Downregulation of MYC-Dependent Proliferation.. Blood, 2009, 114, 1697-1697.	1.4	1
119	High Dose BCNU/Melphalan Preparative Regimen Doubles Event Free Survival of Myeloma Patients Undergoing Autologous Transplantation. Blood, 2011, 118, 2012-2012.	1.4	1
120	Pilot Study of Sorafenib for Myelodysplastic Syndrome. Blood, 2012, 120, 4948-4948.	1.4	1
121	DNA Demethylation Activity Over Time and Safety Of 3 Different Dose-Escalation Regimens Of SGI-110, a Novel Subcutaneous (SQ) Hypomethylating Agent (HMA), In The Treatment Of Relapsed/Refractory Patients With MDS and AML. Blood, 2013, 122, 1548-1548.	1.4	1
122	A phase I trial of ipilimumab (ipi) in patients (pts) with myelodysplastic syndromes (MDS) after hypomethylating agent (HMAs) failure.. Journal of Clinical Oncology, 2017, 35, 7010-7010.	1.6	1
123	Phase I/II dose expansion of a trial investigating bendamustine and pomalidomide with dexamethasone (BPd) in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology, 2017, 35, 8008-8008.	1.6	1
124	Antiproliferative Activity of ELACYTâ„¢ (CP-4055) in Combination with Cloretazine (VNP40101M), Idarubicin or Gemcitabine in HL-60 Human Myeloid Leukemia Cells.. Blood, 2006, 108, 1991-1991.	1.4	1
125	Myeloablative Intravenous Busulfan/Fludarabine Conditioning Does Not Facilitate Reliable Engraftment of Dual Umbilical Cord Blood Grafts in Adult Recipients.. Blood, 2007, 110, 2007-2007.	1.4	1
126	Apolipoprotein E (APOE) Genotype as a Determinant of Survival in Women with Chronic Lymphocytic Leukemia.. Blood, 2007, 110, 3081-3081.	1.4	1



#	ARTICLE	IF	CITATIONS
127	Immunocompromised Status of Patients with Hematologic and Solid Tumor Malignancies: Construction of a Practical Algorithm.. Blood, 2009, 114, 2484-2484.	1.4	1
128	Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical) Tj ETQq0 0 0 ngBT /Overlock 10 Tf		
129	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline. Blood, 2012, 120, 46-46.	1.4	1
130	Shared decision-making tools for patients with hematologic malignancies.. Journal of Clinical Oncology, 2016, 34, e19007-e19007.	1.6	1
131	Allogeneic Stem Cell Transplantation with Omidubicel: Long-Term Follow-up from a Single Center. Blood, 2021, 138, 1827-1827.	1.4	1
132	A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138, 4429-4429.	1.4	1
133	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. Blood, 2021, 138, 3134-3134.	1.4	1
134	355â€œ...First-in-human phase I study of NKTR-255 in patients with relapsed/refractory hematologic malignancies. , 2020, , .		1
135	Is Timing Everything?. Biology of Blood and Marrow Transplantation, 2014, 20, 145-146.	2.0	0
136	Clinical and Neuroimaging Correlates of Post-Transplant Delirium. Biology of Blood and Marrow Transplantation, 2020, 26, 2323-2328.	2.0	0
137	CLORETAZINEâ„¢ (VNP40101M) Is Active in Elderly Untreated Poor Risk Patients with Acute Myelogenous Leukemia (AML) or High Risk Myelodysplasia (MDS).. Blood, 2005, 106, 2786-2786.	1.4	0
138	Multimodal Dose Dense Therapy for Mantle Cell Lymphoma.. Blood, 2005, 106, 5501-5501.	1.4	0
139	Phase I Study of Gemcitabine, Fludarabine and Mitoxantrone for Relapsed or Refractory Leukemia.. Blood, 2005, 106, 4623-4623.	1.4	0
140	Efficacy of Performing a Second Non-Myeloablative Allogeneic Stem Cell Transplant.. Blood, 2005, 106, 3664-3664.	1.4	0
141	Predictors of Survival in CLL: Multivariate Analyses Reveal Significant Correlation with IgVH Gene Mutation Status, Clinical Stage, and Cellular CD38 (but Not Zap-70) Expression.. Blood, 2005, 106, 5010-5010.	1.4	0
142	Use of a Disease-Specific Comorbidity Index To Describe Elderly Patients with Acute Myelogenous Leukemia (AML) and High Risk Myelodysplasia (MDS) Enrolled in a Phase II Study of CLORETAZINEâ„¢ (VNP40101M).. Blood, 2005, 106, 2787-2787.	1.4	0
143	A Phase I Study with CP-4055 In Patients with Hematologic Malignancies.. Blood, 2007, 110, 901-901.	1.4	0
144	Total Body Irradiation 1350cGy/Fludarabine (TBI/FLU) vs Myeloablative Busulfan/Fludarabine (Bu/Flu) Preparation in Adult Recipients of Dual Umbilical Cord Blood (UCB) Transplantation: Superior Engraftment with Low Treatment-Related Mortality. Blood, 2008, 112, 4403-4403.	1.4	0

#	ARTICLE	IF	CITATIONS
145	Bortezomib Plus Melphalan and Prednisone as Induction Prior to Transplant or as Frontline Therapy for Non-Transplant Candidates in Patients with Previously Untreated Multiple Myeloma.. Blood, 2008, 112, 3325-3325.	1.4	0
146	Early Pre/Post Fluoro-Deoxyglucose Positive Emission Tomography (PET) Does Not Predict Outcome of Patients Undergoing Hematopoietic Stem Cell Transplantation in Hodgkins Disease and Non-Hodgkins Lymphoma.. Blood, 2008, 112, 2180-2180.	1.4	0
147	Cenersen, An Antisense Inhibitor of p53, in Combination with Fludarabine, Cyclophosphamide, and Rituximab Shows Clinical Activity in High Risk CLL.. Blood, 2009, 114, 3430-3430.	1.4	0
148	A Comprehensive Identification of the Microrna Transcriptome and Its Application in B Cell Malignancies.. Blood, 2009, 114, 2403-2403.	1.4	0
149	Hematopoietic Stem Cell Transplantation Across Genetic Barriers Using a Nonmyeloablative Conditioning Regimen. , 2010, , 119-162.		0
150	Alternative Splicing Is a Major Mechanism of Gene Regulation In Diffuse Large B Cell Lymphoma. Blood, 2010, 116, 803-803.	1.4	0
151	Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350cGy) and Fludarabine Conditioning. Blood, 2010, 116, 3523-3523.	1.4	0
152	Prospective, Biological Randomized Study of T-Cell Depleted Nonmyeloablative Allogeneic Transplantation From HLA-Matched Related, Unrelated or Haploidentical Donors for Patients with Hematologic Malignancies. Blood, 2010, 116, 3541-3541.	1.4	0
153	Donor Cell Leukemia: A Clinicopathological Study of 9 Cases and a Comprehensive Review of Literature.. Blood, 2010, 116, 3466-3466.	1.4	0
154	Results of the OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia. Blood, 2011, 118, 767-767.	1.4	0
155	A Phase I Study of the Combination of Decitabine with Lenalidomide for Patients with High Risk (IPSS) Tj ETQq1 1 0,784314 rgBT /Over	1.4	0
156	Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients. Blood, 2011, 118, 2619-2619.	1.4	0
157	The Impact of Lymphocyte Subset Recovery At 3 Months on Progression-Free Survival After Myeloablative Allogeneic Stem Cell Transplantation,. Blood, 2011, 118, 4065-4065.	1.4	0
158	A Phase II Study of Elacytarabine/Idarubicin As Second Course Remission-Induction in Patients with Acute Myeloid Leukemia Who Failed Cytarabine/Anthracycline, and Evaluation of the Impact of the Nucleoside Transporter hENT1 on Response. Blood, 2011, 118, 1533-1533.	1.4	0
159	A Phase I Study of Arsenic Trioxide (Trisenox), Ascorbic Acid, and Bortezomib (Velcade) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma. Blood, 2011, 118, 5129-5129.	1.4	0
160	A single-arm, open-label, multicenter study of complete molecular response (CMR) in patients with newly diagnosed Philadelphia chromosomeâ€“positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.. Journal of Clinical Oncology, 2012, 30, TPS6636-TPS6636.	1.6	0
161	Initial salvage therapy in first relapse AML: A phase IIb study of CPX-351 versus investigatorâ€™s choiceâ€™”A subset analysis by prognostic group.. Journal of Clinical Oncology, 2012, 30, 6525-6525.	1.6	0
162	Phase 1 Study of Lenalidomide and Decitabine for High and Intermediate 2 Risk MDS. Blood, 2012, 120, 4935-4935.	1.4	0

#	ARTICLE	IF	CITATIONS
163	A Phase 2 Trial of Imatinib Mesylate As Maintenance Therapy for Patients with Newly Diagnosed C-Kit Positive Acute Myeloid Leukemia (AML). <i>Blood</i> , 2012, 120, 3597-3597.	1.4	0
164	Phase II Study of VEGF Inhibitor, PTK787/ZK222584, in Patients with Refractory or Relapsed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2012, 120, 1626-1626.	1.4	0
165	ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom. <i>Blood</i> , 2012, 120, 898-898.	1.4	0
166	Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update. <i>Blood</i> , 2014, 124, 1796-1796.	1.4	0
167	ENESTnext Final Results: Deep Molecular Response (MR) with Nilotinib (NIL) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). <i>Blood</i> , 2015, 126, 4048-4048.	1.4	0
168	A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7071-TPS7071.	1.6	0
169	Molecular testing during AML treatment for early prediction of clinical response.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7047-7047.	1.6	0
170	Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Term Follow up from Phase 2 Study of 103 Patients. <i>Blood</i> , 2019, 134, 1319-1319.	1.4	0
171	Pre-Transplant Hepatic Steatosis (fatty liver) Predicts Chronic Graft-Vs-Host Disease but Does Not Affect Mortality. <i>Blood</i> , 2019, 134, 5731-5731.	1.4	0
172	Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. <i>Blood</i> , 2021, 138, 2318-2318.	1.4	0
173	Tagraxofusp, an Anti-CD123 Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm: Subanalyses of a Pivotal Trial By Age and Baseline Disease Involvement. <i>Blood</i> , 2021, 138, 874-874.	1.4	0
174	Female Gender Is Associated with Improved Long-Term Survival Following Allogeneic Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2020, 136, 18-19.	1.4	0
175	Chemoimmunotherapy's potential to impact paroxysmal nocturnal hemoglobinuria. <i>Clinical Advances in Hematology and Oncology</i> , 2012, 10, 136-7.	0.3	0